Unmet Needs and Future Directions in Progressive Pancreatic Neuroendocrine Tumor

In the closing segment, Dr Shaheen reflects on unmet needs and future directions for patients with advanced pancreatic neuroendocrine tumors. She acknowledges that while treatment options have expanded, significant gaps remain in optimizing sequencing, predicting response, and maintaining long term quality of life.

One unmet need discussed is the lack of biomarkers to guide therapy selection. Dr Shaheen notes that clinicians often rely on clinical judgment rather than predictive tools when choosing among multiple reasonable options. Improved biomarkers could help personalize sequencing and reduce unnecessary toxicity.

She also highlights the need for additional therapies that provide durable disease control without cumulative side effects. As patients live longer with metastatic NETs, the challenge becomes managing disease as a chronic condition rather than a series of isolated treatment decisions.

Dr Shaheen points to ongoing research into novel agents and combination strategies as a source of cautious optimism. She emphasizes the importance of continued clinical trial participation to expand evidence for later line settings and special populations.

The segment concludes with a forward looking perspective that balances progress with realism. While current therapies offer meaningful benefit, advancing care for pancreatic NETs will require better tools, more tailored approaches, and continued focus on patient centered outcomes.